The studies count a reduction in stroke as part of the main goal on which they will measure success or failure.

FORBES: Merck Learns There Is No Magic Pill

If AtheroGenics had set heart attack, stroke and death as the main goal of its study, these results could lead to approval by the U.S. Food and Drug Administration.

FORBES: Strange Days For AtheroGenics

Timing is the main factor determining whether a person lives or dies -- or lives with a severe disability -- after a stroke.

CNN: Stroke recovery: One woman's story